pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Kailera Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Kailera Therapeutics.
Kailera Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Drug GC4711
Galera Therapeutics
SBRT
1 trial -
Drug: GC4419
Galera Therapeutics
Head and Neck Cancer
1 trial -
GC4419
Galera Therapeutics
Covid19
1 trial -
GC4419
Galera Therapeutics
Pancreatic Cancer
1 trial -
GC4419 (avasopasem manganese)
Galera Therapeutics
Esophagitis
1 trial -
GC4711 +SBRT
Galera Therapeutics
SBRT
1 trial -
Low Dose GC4419: 30mg/day
Galera Therapeutics
Radiation Induced Oral Mucositis
1 trial
Frequently asked questions
How many clinical projects does Kailera Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.